| ¿µ¹® | serum enzyme | ÇÑ±Û | Ç÷ûȿ¼Ò |
|---|---|---|---|
| ¼³¸í | Ç÷û ³»¿¡ Æ÷ÇԵǾî ÀÖ´Â ¿©·¯ °¡Áö È¿¼Ò¸¦ ÀÏÄ´ ¸»ÀÌ´Ù. |
||
| ¿µ¹® | enzyme | ÇÑ±Û | È¿¼Ò |
|---|---|---|---|
| ¼³¸í | »ý¹°Ã¼ ¼¼Æ÷¼Ó¿¡¼ ÇÕ¼ºµÇ°í, ÁÖ·Î ¼¼Æ÷³»¿¡¼ ÁøÇàµÇ´Â ÈÇйÝÀÀÀ» Ã˸ÅÇÏ´Â ´Ü¹éÁú·Î ½ÃÇè°ü³»¿¡¼µµ °°Àº Ã˸ÅÀÛ¿ëÀ» ÇÑ´Ù. ÀÌ È¿¼Ò´Â ÀΰøÀûÀ¸·Î ¸¸µç ¾î¶² Ã˸ÅÁ¦º¸´Ù ±× ƯÀ̼º°ú Ã˸ÅÀÛ¿ëÀÌ Å¹¿ùÇÑ Æ¯º°ÇÑ »ýüºÐÀÚÀÌ´Ù. ½ÅÁø´ë»ç, Áï ¼¼Æ÷³»¿¡¼ ÀϾ´Â ¹°ÁúÀÇ ÈÇÐÀû º¯È¯Àº È¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ¸Å¿ì ºü¸£°í ¿øÇÒÇÏ°Ô ÀÌ·ç¾îÁø´Ù. À̰ÍÀº È¿¼ÒÀÇ Ã˸ŠȿÀ²ÀÌ ³ôÀº Á¡°ú È¿¼ÒÀÇ ±âÁú ƯÀ̼º ¶§¹®ÀÌ´Ù. È¿¼Ò¹ÝÀÀÀº »ó¿Â, »ó¾Ð, ÃÖÀû pH µî ÀûÀýÇÑ Á¶°Ç ¾Æ·¡¿¡¼ ÁøÇàµÈ´Ù. ¶Ç È¿¼ÒÀÇ ÁÖü°¡ ´Ü¹éÁúÀ̱⠶§¹®¿¡ ´Ü¹éÁúÀ» º¯¼º½ÃŰ´Â ¿, °»ê, °¾ËÄ®¸®, À¯±â¿ë¸Å µî¿¡ ÀÇÇØ ±× ÀÛ¿ëÀ» ÀҴ´Ù. È¿¼Ò´Â »ýü¿¡ ³Î¸® ºÐÆ÷Çϸç, º¹ÀâÇÏ°í ´Ù¾çÇÑ ´ë»ç¹ÝÀÀÀ» Ã˸ÅÇϱ⠶§¹®¿¡ Á¾·ùµµ ¸¹´Ù. ¾Õ¼ ¸»ÇÑ ¹Ù¿Í °°ÀÌ ´ëºÎºÐÀÇ È¿¼Ò´Â ¼¼Æ÷³»¿¡ Á¸ÀçÇÏÁö¸¸, Ç÷¾×°ú ±×¿ÜÀÇ °£Áú¾×¿¡ µé¾î Àֱ⵵ ÇÏ°í ¼ÒÈÈ¿¼Ò·ùó·³ ü¿Ü·Î ºÐºñµÇ´Â °Íµµ ÀÖ´Ù. |
||
| ¿µ¹® | enzyme-linked immunoabsorbent assay | ÇÑ±Û | È¿¼Ò¸é¿ªÃøÁ¤¹ý |
|---|---|---|---|
| ¼³¸í | È¿¼Ò°áÇո鿪ÈíÂøÁ¦ °ËÁ¤¹ýÀ¸·Î ¹ø¿ªµÇ°í ÀÖ´Ù. ÀÌ ¹ýÀº Ç׿ø(¶Ç´Â Ç×ü)¿¡ ¾ËÄ®¸® Æ÷½ºÆÄŸ¾ÆÁ¦ ¶Ç´Â Æä¸£¿Á½Ãµð¾ÆÁ¦ µîÀÇ »ê¼Ò¸¦ °áÇÕ½ÃÄÑ µÎ°í ±× »ê¼ÒȰ¼ºÀ» ÁöÇ¥·Î »ï¾Æ Ç׿øÇ×ü¹ÝÀÀÀÇ Á¤µµ¸¦ ¾È ´ÙÀ½ ¿©±â¿¡¼ Ç׿ø(¶Ç´Â Ç×ü)ÀÇ ¾çÀ» ±¸ÇÏ´Â °ÍÀÌ´Ù. ÀÌ ¹ýÀÇ ÀÌÁ¡À¸·Î¼ °í°¨µµ, Á¶ÀÛÀÇ °£´ÜÇÔ ¹× ¹æ»ç¼±¸é¿ªÃøÁ¤¹ýó·³ ¹æ»ç¼º¹°ÁúÀ» »ç¿ëÇÏÁö ¾Ê¾Æµµ µÈ´Ù´Â Á¡À» µé ¼ö ÀÖ´Ù. È£¸£¸óÀ̳ª ¸é¿ª±Û·ÎºÒ¸°ÀÇ Á¤·®¹ýÀ¸·Î¼ ÀÀ¿ë µÇ°í ÀÖÀ¸¸ç ÃøÁ¤¿ë ŰƮµµ ½ÃÆÇµÇ°í ÀÌÀÖ´Ù. |
||
| MAOI | MonoAmine Oxidase Inhibitors |
|---|---|
| EIA | electroimmunoassay; enzyme immunoassay; enzyme-linked immunosorbent assay; equine infectious anemia;... |
| PACE | Pacing and Clinical Electrophysiology; paired basic amino acid cleaving enzyme; personalized aerobic... |
| ACE | Angiotensin Converting Enzyme = Kininase II = Dipeptidyl Carboxypepti... |
| EIA | 1) Exercise Induced Asthma; ¿îµ¿ À¯¹ß¼º õ½Ä = EIB 2) Enzyme Immu... |
| AChE-I | acetylcholine esterase inhibitors |
|---|---|
| ChEI | Cholinesterase inhibitors |
| IAPs | Inhibitors of apoptosis |
| NNRTI | Non nucleoside reverse transcriptase inhibitors |
| PAI | Plasminogen Activator Inhibitors |
| enzyme inhibitors | Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (12 Dec 1998) |
|---|---|
| enzymes, coenzymes, and enzyme inhibitors | Proteins or RNA that act as biological catalysts, their cofactors, and inhibitors. (12 Dec 1998) |
| adrenergic uptake inhibitors | Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (antidepressive agents, tricyclic) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (12 Dec 1998) |
| blood coagulation factor inhibitors | Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria. (12 Dec 1998) |
| Bowman Birk protease inhibitors | <pharmacology> Family of serine protease inhibitors found in seeds of leguminous plants and cereals. (18 Nov 1997) |
| carbonic anhydrase inhibitors | A class of compounds that reduces the secretion of h+ ions by the proximal kidney tubule through inhibition of carbonic anhydrase (carbonate dehydratase). Although their therapeutic use as diuretics is not frequent, they are used in clinical conditions where alkalinization of the urine is beneficial. Their most frequent application is in the reduction of intra-ocular pressure in the treatment of glaucoma. (12 Dec 1998) |
| reverse transcriptase inhibitors | Inhibitors of reverse transcriptase (RNA-directed DNA polymerase), an enzyme that synthesises DNA on an RNA template. (12 Dec 1998) |
| growth inhibitors | Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators). (12 Dec 1998) |
| phosphodiesterase inhibitors | Compounds which inhibit or antagonise the biosynthesis or actions of phosphodiesterases. (12 Dec 1998) |
| monoamine oxidase inhibitors | A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. Although mao inhibitors are probably as effective as tricyclic antidepressants in the treatment of major depression, the complex, sometimes severe, and often unpredictable interactions between mao inhibitors and many other drugs and food-derived amines make their medical use difficult and potentially hazardous. (12 Dec 1998) |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
| cysteine proteinase inhibitors | Exogenous and endogenous compounds which inhibit cysteine proteinases. (12 Dec 1998) |
| protease inhibitors | Compounds which inhibit or antagonise biosynthesis or actions of proteases. (12 Dec 1998) |
| HIV integrase inhibitors | Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA. (12 Dec 1998) |
| HIV protease inhibitors | Inhibitors of HIV protease, an enzyme required for production of proteins needed for viral assembly. (12 Dec 1998) |
Synonyms : Angiotensin I-Converting Enzyme Inhibitors, Angiotensin-Converting Enzyme Antagonists, Antagonists, Angiotensin-Converting Enzyme, Antagonists, Kininase II, Inhibitors, ACE, Inhibitors, Angiotensin-Converting Enzyme, Inhibitors, Kininase II
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|